Table 1.
Baseline characteristics by salvage status
| Characteristica | Salvage 1 (n=46) |
Salvage 2 (n=32) |
All patients (N=78) |
|---|---|---|---|
| Age (years) | 38 (18–87) | 38 (19–79) | 38 (18–87) |
| WBC (109/L) | 3.2 (0.5–36.8) | 2.9 (0.3–37.6) | 3.1 (0.3–37.6) |
| Hemoglobin (g/dL) | 10.0 (7.6–15.9) | 10.3 (7.7–14.4) | 10.1 (7.6–15.9) |
| Platelets (109/L) | 98 (9–394) | 37 (7–286) | 64 (7–394) |
| BM blasts (%) | 64 (8–97) | 51 (10–96) | 61 (8–97) |
| LDH (U/L) | 551 (231–9043) | 695 (266–19165) | 585 (231–19165) |
| CNS disease | 2 (4) | 0 (0) | 2 (3) |
| Cytogenetics | |||
| Diploid | 13 (28) | 6 (19) | 19 (24) |
| t(9;22) | 2 (4) | 2 (6) | 4 (5) |
| t(4;11) | 6 (13) | 1 (2) | 7 (9) |
| Others | 25 (54) | 23 (72) | 48 (62) |
| Performance status | |||
| 0–1 | 44 (96) | 29 (91) | 73 (94) |
| 2–4 | 2 (4) | 3 (9) | 5 (6) |
| Disease status | |||
| Refractory | 9b (20) | 19 (59) | 28 (36) |
| Relapsed | 36 (80) | 13 (41) | 49 (64) |
| Prior SCT | 5 (11) | 6 (19) | 11 (14) |
| Salvage Treatment | |||
| Inotuzumab | 21 (46) | 20 (63) | 41 (53) |
| Blinatumomab | 4 (9) | 7 (22) | 11 (14) |
| HCVD+ino | 21 (46) | 5 (16) | 26 (33) |
a
Continuous variables are listed as median (range) and categorical variables as n (%)
b
One patient in first salvage who received HCVD+ino did not have a documented response to last treatment
WBC, white blood cells; BM, bone marrow; LDH, lactate dehydrogenase; CNS, central nervous system; SCT, stem cell transplant; HCVD+ino; hyperfractionated cyclophosphamide, vincristine and dexamethasone plus inotuzumab